Estee Lauder Stock Dips As Puig Deal Dies And Portfolio Sale Nears

Estee Lauder Companies Inc. (The) stocks have been trading up by 11.92 percent amid strong earnings-driven investor optimism.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading EL

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

What Traders Need To Know

End of merger talks with Puig shifts focus back to Estée Lauder’s “Beauty Reimagined” and “One ELC” standalone strategy, reducing M&A headline risk but removing takeover optionality.
Piper Sandler started coverage with an Overweight rating and a $95 price target, pointing to improving organic growth, Americas stabilization, and early FY27 guidance for a top-line inflection.
Rothschild & Co Redburn lifted its target to $70 from $65, while the Street’s average target near $93 still implies upside from current depressed pricing.
Final bids are in for Too Faced, Smashbox, and Dr. Jart, with a sale decision expected within weeks, making brand divestitures a potential near-term catalyst for margins and capital.
Ongoing Jo Malone trademark dispute with Zara adds legal noise but does not outweigh strategy, portfolio, and analyst signals driving Estee Lauder’s current tape.

Weekly Update May 18 – May 22, 2026: On Friday, May 22, 2026 Estee Lauder Companies Inc. (The) stock [NYSE: EL] is trending up by 11.92%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Consumer Staples industry expert:

Analyst sentiment – positive

Estee Lauder remains a global prestige beauty leader but is operating well below its historical earnings power. Revenue of ~$14.3bn is essentially flat over five years with a 3–4% three‑year decline, signaling demand and channel normalization issues versus sector peers compounding mid‑single digits. Gross margin is exceptionally strong at ~74%, yet EBIT margin of 3.9% and negative LTM net margin and ROE highlight heavy overhead and restructuring drag. Leverage is elevated (D/E 2.33x, interest cover 4x), but liquidity is adequate and FCF of ~$310m in the latest quarter comfortably funds the 1.8% dividend.

Technically, the stock is transitioning from a volatility spike to an emerging uptrend. After a capitulation low near $76 on 5/19, price surged to an intraday high above $91 on 5/21 before consolidating in the high‑80s, closing at $88.32 on 5/22. Five‑minute candles show narrowing ranges and firmer bid support above $86, with volume heavier on up‑moves than pullbacks. The key actionable level is ~$85; above it, risk‑reward favors long positions, with tight stops just below $82 to respect lingering event‑risk.

More Breaking News

Fundamentally and versus Consumer Staples and Household & Personal peers, EL’s margins, ROIC and leverage are currently inferior, but its brand equity and restructuring (Beauty Reimagined, Profit Recovery & Growth) position it for outsized earnings recovery. Terminating Puig merger talks removes deal overhang and reinforces a standalone, portfolio‑rationalization story, including potential value from divesting Too Faced, Smashbox, and Dr. Jart. I see upside to $95 over 12 months, with near‑term support at $82–85 and resistance at $92–95.

Quick Financial Overview

Estee Lauder Companies Inc. (The) is in the middle of a strategic reset while the stock trades in a volatile band. Weekly data show EL bouncing from $76 to a recent close near $88, with a sharp move up on 2026/05/21 after merger talks with Puig were officially ended and management doubled down on the “Beauty Reimagined” and “One ELC” standalone plan. That day’s range from roughly $79 to over $91 tells you volatility is live and headline-driven. For short-term traders, this is a catalyst tape, not a sleepy consumer staple.

Intraday, the latest 5‑minute chart shows EL grinding higher through the session, opening around the high‑80s, dipping toward $86, then pushing back to close near $88.60 with steady higher lows through the afternoon. That is classic accumulation behavior after a news shock, with dip buyers stepping in rather than a straight fade. Intraday support sits in the mid‑$86 area, while the $90–$91 zone from the weekly spike is the first obvious resistance band to watch.

Fundamentally, Estee Lauder printed about $3.71B in quarterly revenue and $462M in EBITDA, but net income of $89M translates into a slim 3.9% EBIT margin and negative trailing profit margin despite a rich 74.3% gross margin. The gap between gross and net margins is what the Profit Recovery & Growth Program is trying to close. Operating cash flow of $412M and free cash flow of $310M for the quarter are solid relative to a roughly $37.8B enterprise value, but not cheap, with price‑to‑sales around 1.9 and price‑to‑free‑cash near 20.2. Leverage is meaningful, with total debt‑to‑equity at 2.33 and long‑term debt near $8.4B, so any brand sales from Too Faced, Smashbox, and Dr. Jart will matter for balance sheet flexibility.

Conclusion

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!